Critical

Paroxysmal nocturnal haemoglobinuria (PNH)

Haemolysis / thrombosis · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

An acquired clonal stem-cell disorder causing complement-mediated intravascular haemolysis, thrombosis (often at unusual sites) and a degree of marrow failure. Presents with dark morning urine, anaemia, abdominal/back pain, and — the leading cause of death — venous thrombosis, classically Budd-Chiari (hepatic vein) or cerebral/abdominal veins. Overlaps with aplastic anaemia.

Red flags

  • Abdominal pain + ascites / deranged LFTs — Budd-Chiari (hepatic vein thrombosis)
  • Headache, seizure or focal deficit — cerebral venous sinus thrombosis
  • Severe symptomatic anaemia / haemoglobinuria
  • New thrombosis at any unusual site
  • Fever during haemolysis — infection-triggered crisis

Assessment

Differential diagnosis

  • Other intravascular haemolysis — G6PD, autoimmune haemolytic anaemia, mechanical (valve), microangiopathy (TTP/HUS/DIC)
  • Aplastic anaemia / MDS (overlap)
  • Provoked/unprovoked thrombosis of other cause
  • Rhabdomyolysis / myoglobinuria (red urine, no red cells)
  • Transfusion reaction
  • Wilson disease / other haemolytic crises

Investigations

  • FBC + reticulocytes + film; LDH markedly raised, haptoglobin low, unconjugated bilirubin up
  • Direct antiglobulin test (DAT/Coombs) NEGATIVE (non-immune haemolysis)
  • Urinalysis — haemoglobinuria (blood positive, few/no red cells); urinary haemosiderin
  • FLOW CYTOMETRY for GPI-deficient cells (FLAER) — the diagnostic test
  • D-dimer/imaging if thrombosis suspected (Doppler, CT/MR venography for Budd-Chiari/cerebral veins)
  • U&E, LFTs; iron studies (chronic urinary iron loss)

Management

  • Recognise Coombs-NEGATIVE intravascular haemolysis with thrombosis and confirm by flow cytometry
  • Treat/anticoagulate thrombosis promptly — it is the main killer (e.g. Budd-Chiari, cerebral venous sinus)
  • Supportive care: transfuse for symptomatic anaemia, folic acid, iron for urinary losses
  • Urgent haematology referral — definitive therapy is complement inhibition (eculizumab / ravulizumab)
  • Ensure meningococcal vaccination/prophylaxis before/around starting a complement inhibitor
  • Treat infection promptly (it triggers haemolytic exacerbations)
  • Manage marrow-failure overlap as for aplastic anaemia if pancytopenic

Drugs & doses

Anticoagulation (thrombosis — LMWH/DOAC/warfarin per site)
Red cells (symptomatic anaemia)
Folic acid; iron for urinary iron loss
Complement inhibitor — eculizumab / ravulizumab (specialist)
Empirical antibiotics per BNF — see the in-app Antibiotic Dosing tool

Disposition

Admit under haematology; anticoagulate and image for thrombosis; specialist complement-inhibitor therapy.

Complications & pitfalls

  • Venous thrombosis at unusual sites (leading cause of death)
  • Renal impairment (chronic haemoglobinuria)
  • Pulmonary hypertension
  • Progression to aplastic anaemia / MDS / AML
  • Meningococcal sepsis on complement inhibitors

Exam pearls

  • Coombs-NEGATIVE intravascular haemolysis + thrombosis (esp. Budd-Chiari) should trigger PNH testing by flow cytometry
  • Thrombosis — not anaemia — is what kills; anticoagulate promptly and have a low threshold to image unusual sites
  • Vaccinate against meningococcus before starting a complement inhibitor and give antibiotic cover
  • Chronic urinary iron loss means these patients can be iron-deficient despite haemolysis

PNH thrombosis (classically Budd-Chiari or cerebral venous) is the leading cause of death — anticoagulate promptly and refer for complement inhibition (with prior meningococcal cover). Antibiotic doses per BNF (current edition); confirm choice in the in-app Antibiotic Dosing tool.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.